KLK3 and prostate carcinoma: Results from the Prostate Cancer Prevention Trial found that a PSA threshold of 1.1ng/mL was required to achieve a sensitivity of 83.4%, but at the price of a false-positive rate of 61.1% (i.e. specificity = 39.9%)[6].